Valproate therapy for agitation in dementia

Open-label extension of a double-blind trial

Anton P. Porsteinsson, Pierre N. Tariot, Laura J. Jakimovich, Nancy Kowalski, Connie Holt, Rosemary Erb, Christopher Cox

Research output: Contribution to journalArticle

Abstract

Objective: The authors describe an open-label extension of a double-blind, randomized, placebo-controlled study of divalproex sodium in 56 nursing home patients with agitation and dementia. Methods: Participants (N = 46) were treated for 6 weeks in an open fashion with clinically optimal doses of divalproex sodium (range: 250 mg/day-1,500 mg/day; mean: 851 mg/day). Behavior was assessed with the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression of Change (CGI) by new raters. Safety, tolerability, and laboratory data were obtained regularly. Results: The mean BPRS Agitation Factor decreased by 3.1 points from baseline; 86% of those completing the open phase were rated as improved on the CGI. These changes were mirrored by changes in other behavior rating scales. Sixty percent of subjects had no side effects; 33% had side effects that were rated as mild. There were no clinically significant changes in laboratory values. Conclusion: Ongoing open-label treatment with divalproex was associated with improvement in measures of agitation. Doses, levels, and tolerability were similar to those in the blinded phase of the study. These findings help confirm and extend the results from the placebo-controlled phase of the trial and suggest that divalproex may be beneficial for some patients with this clinical problem.

Original languageEnglish (US)
Pages (from-to)434-440
Number of pages7
JournalAmerican Journal of Geriatric Psychiatry
Volume11
Issue number4
DOIs
StatePublished - 2003
Externally publishedYes

Fingerprint

Valproic Acid
Dementia
Brief Psychiatric Rating Scale
Placebos
Therapeutics
Nursing Homes
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology

Cite this

Valproate therapy for agitation in dementia : Open-label extension of a double-blind trial. / Porsteinsson, Anton P.; Tariot, Pierre N.; Jakimovich, Laura J.; Kowalski, Nancy; Holt, Connie; Erb, Rosemary; Cox, Christopher.

In: American Journal of Geriatric Psychiatry, Vol. 11, No. 4, 2003, p. 434-440.

Research output: Contribution to journalArticle

Porsteinsson, Anton P. ; Tariot, Pierre N. ; Jakimovich, Laura J. ; Kowalski, Nancy ; Holt, Connie ; Erb, Rosemary ; Cox, Christopher. / Valproate therapy for agitation in dementia : Open-label extension of a double-blind trial. In: American Journal of Geriatric Psychiatry. 2003 ; Vol. 11, No. 4. pp. 434-440.
@article{68364539768340459695adc737d528ff,
title = "Valproate therapy for agitation in dementia: Open-label extension of a double-blind trial",
abstract = "Objective: The authors describe an open-label extension of a double-blind, randomized, placebo-controlled study of divalproex sodium in 56 nursing home patients with agitation and dementia. Methods: Participants (N = 46) were treated for 6 weeks in an open fashion with clinically optimal doses of divalproex sodium (range: 250 mg/day-1,500 mg/day; mean: 851 mg/day). Behavior was assessed with the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression of Change (CGI) by new raters. Safety, tolerability, and laboratory data were obtained regularly. Results: The mean BPRS Agitation Factor decreased by 3.1 points from baseline; 86{\%} of those completing the open phase were rated as improved on the CGI. These changes were mirrored by changes in other behavior rating scales. Sixty percent of subjects had no side effects; 33{\%} had side effects that were rated as mild. There were no clinically significant changes in laboratory values. Conclusion: Ongoing open-label treatment with divalproex was associated with improvement in measures of agitation. Doses, levels, and tolerability were similar to those in the blinded phase of the study. These findings help confirm and extend the results from the placebo-controlled phase of the trial and suggest that divalproex may be beneficial for some patients with this clinical problem.",
author = "Porsteinsson, {Anton P.} and Tariot, {Pierre N.} and Jakimovich, {Laura J.} and Nancy Kowalski and Connie Holt and Rosemary Erb and Christopher Cox",
year = "2003",
doi = "10.1097/00019442-200307000-00006",
language = "English (US)",
volume = "11",
pages = "434--440",
journal = "American Journal of Geriatric Psychiatry",
issn = "1064-7481",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Valproate therapy for agitation in dementia

T2 - Open-label extension of a double-blind trial

AU - Porsteinsson, Anton P.

AU - Tariot, Pierre N.

AU - Jakimovich, Laura J.

AU - Kowalski, Nancy

AU - Holt, Connie

AU - Erb, Rosemary

AU - Cox, Christopher

PY - 2003

Y1 - 2003

N2 - Objective: The authors describe an open-label extension of a double-blind, randomized, placebo-controlled study of divalproex sodium in 56 nursing home patients with agitation and dementia. Methods: Participants (N = 46) were treated for 6 weeks in an open fashion with clinically optimal doses of divalproex sodium (range: 250 mg/day-1,500 mg/day; mean: 851 mg/day). Behavior was assessed with the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression of Change (CGI) by new raters. Safety, tolerability, and laboratory data were obtained regularly. Results: The mean BPRS Agitation Factor decreased by 3.1 points from baseline; 86% of those completing the open phase were rated as improved on the CGI. These changes were mirrored by changes in other behavior rating scales. Sixty percent of subjects had no side effects; 33% had side effects that were rated as mild. There were no clinically significant changes in laboratory values. Conclusion: Ongoing open-label treatment with divalproex was associated with improvement in measures of agitation. Doses, levels, and tolerability were similar to those in the blinded phase of the study. These findings help confirm and extend the results from the placebo-controlled phase of the trial and suggest that divalproex may be beneficial for some patients with this clinical problem.

AB - Objective: The authors describe an open-label extension of a double-blind, randomized, placebo-controlled study of divalproex sodium in 56 nursing home patients with agitation and dementia. Methods: Participants (N = 46) were treated for 6 weeks in an open fashion with clinically optimal doses of divalproex sodium (range: 250 mg/day-1,500 mg/day; mean: 851 mg/day). Behavior was assessed with the Brief Psychiatric Rating Scale (BPRS) and Clinical Global Impression of Change (CGI) by new raters. Safety, tolerability, and laboratory data were obtained regularly. Results: The mean BPRS Agitation Factor decreased by 3.1 points from baseline; 86% of those completing the open phase were rated as improved on the CGI. These changes were mirrored by changes in other behavior rating scales. Sixty percent of subjects had no side effects; 33% had side effects that were rated as mild. There were no clinically significant changes in laboratory values. Conclusion: Ongoing open-label treatment with divalproex was associated with improvement in measures of agitation. Doses, levels, and tolerability were similar to those in the blinded phase of the study. These findings help confirm and extend the results from the placebo-controlled phase of the trial and suggest that divalproex may be beneficial for some patients with this clinical problem.

UR - http://www.scopus.com/inward/record.url?scp=0038679746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038679746&partnerID=8YFLogxK

U2 - 10.1097/00019442-200307000-00006

DO - 10.1097/00019442-200307000-00006

M3 - Article

VL - 11

SP - 434

EP - 440

JO - American Journal of Geriatric Psychiatry

JF - American Journal of Geriatric Psychiatry

SN - 1064-7481

IS - 4

ER -